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Abstract
Wegener’s granulomatosis (WG) is a systemic disorder characterized by necrotizing vasculitis involving the
respiratory tract, and in most cases, the kidneys. The most common manifestation of WG in the kidneys is
segmental necrotizing glomerulonephritis. The presence of a renal mass as a manifestation of WG is rare. We
report a patient with WG in whom a CT scan revealed an infiltrating mass in the lower portion of the left kidney.
After surgical exploration, we performed an open radical nephrectomy. Histopathology showed clear cell type renal
cell carcinoma (RCC). RCC associated with WG has been reported in only a few cases, and in most of them, the
diseases started simultaneously, suggesting common pathogenetic pathways. Long-term immunosuppressive
treatment is a known risk factor in the development of malignancies, so occurrence of RCC in WG has been
proposed as a side effect of cyclophosphamide treatment. Furthermore, it is important to make a differential
diagnosis between RCC and pseudotumors in WG as they cannot be distinguished solely on basis of imaging
findings. Due to the higher risk of urologic malignancies, more frequent checkups and screening of WG patients
should be considered.
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Background
Wegener’sg r a n u l o m a t o s i s( W G )i sad i s e a s eo f
unknown etiology characterized by systemic necrotizing
granulomatous vasculitis, which primarily involves the
upper respiratory tract and the lungs. Although renal
involvement is present in only 20% of patients at time
of diagnosis, it eventually occurs in approximately 80%
of all patients suffering from WG. The most common
manifestation of WG in the kidney is segmental necro-
tizing glomerulonephritis with proteinuria that often
leads to rapidly progressive renal failure [1]. The pre-
sence of a renal mass in patients with WG is rare; only
a few cases have been reported [2-7]. Pathologic analysis
of the masses in these cases revealed them to be pseu-
dotumors or renal cell carcinoma (RCC). In most cases
reporting WG and RCC, the diseases developed
simultaneously.
Cyclophosphamide is a mainstay therapy for WG [8].
There is up to 33-fold increased risk for development of
urinary bladder carcinoma, and the risk is cumulative
dose dependent and related to the duration of therapy
with cyclophosphamide [9]. However, RCC development
with cyclophosphamide therapy has been reported in
only few cases and a direct connection is yet to be
determined [3,4].
We report a case in which renal cancer developed
thirteen years after WG was diagnosed.
Case Presentation
Our patient is a 55-year-old man. His symptoms started
in November 1996 with a high fever and cough. About
ten days later, he developed joint, back, and chest pains,
epistaxis, hemoptysis, dyspnea, and a vesicular hemor-
rhagic rash. He lost 15 kg in one month upon which, he
was hospitalized.
The patient presented with a high fever, blood pres-
sure at 135/110 mmHg, hemoglobin at 14 g/dl, an ery-
throcyte sedimentation rate of 80 mm/h, white blood
cell count of 7,5 × 10
9/L, and platelet count of 200 ×
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9/L. A 24-hour urinary protein excretion was mea-
sured at 0.9 g/L with microscopic hematuria, and he
had a positive serum test for antineutrophil cytoplasmic
antibodies (ANCA). A chest x-ray showed multiple nod-
ular and patchy shadows throughout both lungs and a
prominent left hilum. He wasd i a g n o s e dw i t hW Ga n d
started with pulse doses of glucocorticosteroids (IV)
after which cyclophosphamide (IV) was instituted, with
tapering of corticosteroid dose. The symptoms soon
resolved and complete remission was achieved.
In the second year of his ongoing treatment, because
of the development of diabetes mellitus, steroid treat-
ment was stopped, and the therapy was continued with
cyclophosphamide per os only. The patient experienced
two periods of relapse, and after reinstituting therapy
(three pulses of methylprednisolone 500 mg i.v. and
then two pulses of cyclophosphamide 1000 mg, after
two weeks oral cyclophosphamide 100 mg/d therapy
was reinstituted), went into remission. The total cumu-
lative dose of cyclophosphamide was about 150 grams.
Thirteen years later, the patient was admitted to our
hospital due to pain in the left lumbar region, which
began two months earlier. He is a nonsmoker; his body
mass index was 26; with no exposure to occupational
carcinogens, and a negative familial history for renal
malignancies. A CT scan revealed an infiltrating mass,
53 mm at its widest diameter, in the lower portion of
the left kidney (Figure 1). Laboratory analysis of blood
and urine showed normal values while the ANCA test
was negative, suggesting that his WG was still in
remission. After surgical exploration, we performed an
open radical nephrectomy, and a histological examina-
tion revealed a clear cell type renal cell carcinoma, stage
pT3a, grade 2 (Figure 2). In the non-neoplastic kidney
parenchyma there were signs of glomerular sclerosis and
vessels showing fibromuscular hyperplasia (Figure 3). He
is being followed up on regularly and is in remission of
WG and RCC.
Discussion
In 1999, Tatsis et al. [2] reported significant association
between RCC and WG, and suggested that malignancy
Figure 1 Abdominal CT scan revealing an infiltrating mass in lower portion of the left kidney.
Figure 2 Light photomicrograph showing clear cell type renal
cell carcinoma (RCC). H/E staining, 200 × magnification.
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e.g. cytokine production by malignant cells may partici-
pate in the etiology of autoimmunity and vasculitis. In
our patient, RCC developed during the remission of
WG which was diagnosed thirteen years earlier.
Immunosuppressive therapy, primarily cyclophospha-
mide, and steroids have markedly improved survival and
remission rates in WG patients [8]. However, this ther-
apy is associated with a significantly increased risk of
urinary bladder cancer development. The risk is directly
related to the duration of therapy and the total dosage
[9]. In 2009, Deger et al. [3] reported RCC after eight
years of WG treatment with cyclophosphamide and
azathioprine, proposing the possible connection between
immunosuppressive therapy and renal cancer. In 1996,
Odeh [4] reported for the first time, the development of
RCC after treatment with cyclophosphamide in a WG
patient. Our case may also suggest the association of
immunosuppressive therapy with the development of
malignant tumors of the kidney. There were no other
known risk factors for renal cancer in our patient.
Nevertheless, RCC may have developed incidentally.
Further studies are needed to reveal a definitive connec-
tion between WG and RCC as well as the possible influ-
ence of long-term immunosuppressive therapy on the
development of RCC.
In addition, in patients with WG and a renal mass,
there is a differential diagnostic problem. Frigui et al. [5]
reported a review of literature documenting thirteen
cases of renal masses, pathologically verified pseudotu-
mors, as a consequence of WG itself. However, differen-
tial diagnosis between RCC and pseudotumors cannot
be made solely on the basis of imaging findings. Villa-
Forte et al. [10] reported a case of simultaneous
development of RCC and WG renal lesions and pro-
posed renal biopsy to confirm the diagnosis of suspected
WG and repetition of imaging studies to determine the
resolution of mass lesions after appropriate treatment.
Conclusion
In conclusion, we suggest that in WG patients on
immunosuppressive therapy in whom the disease is in a
documented remission, renal masses should be pre-
sumed to be malignant, generally RCC, but carcinoma
of the renal pelvis should also be kept in mind when
dealing with patients with a cyclophosphamide therapy.
Definitive diagnosis can only be made by renal biopsy.
Due to the higher risk of urologic malignancies, more
frequent checkups and screening of WG patients should
also be considered.
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